apl. Prof. Dr. Peter Goebell

Medizinische Fakultät Urologische Klinik

Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example (2016) Sekula P, Pressler JB, Sauerbrei W, Goebell P, Schmitz-Draeger BJ Journal article Taking the next step-Advancing bladder cancer management (2016) Vlahou A, Black PC, Goebell P, Kamat AM, Nawroth R, Schmitz-Draeger BJ Journal article Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines (2016) Schmitz-Draeger BJ, Kuckuck EC, Zuiverloon TCM, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, et al. Journal article Operative therapy of spinal metastases from urological tumors (2016) Richter RH, Hammon M, Uder M, Huber J, Goebell P, Kunath F, Wullich B, Keck B Journal article Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project+ (2015) Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, et al. Journal article Functional analyses and prognostic significance of SFRP1 expression in bladder cancer (2015) Rogler A, Kendziorra E, Giedl J, Stoehr C, Taubert H, Goebell P, Wullich B, et al. Journal article Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study (2015) Bergmann L, Kube U, Doehn C, Steiner T, Goebell P, Kindler M, Herrmann E, et al. Journal article Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma (2015) Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Goebell P, Schick S, et al. Journal article Testosterone Replacement Therapy in Hypogonadal Men Following Prostate Cancer Treatment: A Questionnaire-Based Retrospective Study among Urologists in Bavaria, Germany (2015) Kühn C, Strasser H, Romming A, Wullich B, Goebell P Journal article SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer (2015) Eichelberg C, Vervenne WL, De Santis M, Von Weikersthal LF, Goebell P, Lerchenmueller C, Zimmermann U, et al. Journal article